Feature

The Remarkable Story of Rilzabrutinib

Discover what it takes to deliver a new drug to market. From groundbreaking research at UCSF to ringing the NASDAQ bell, the journey of Rilzabrutinib is a testament to the university's innovation and collaboration. This remarkable autoimmune drug propelled Principia Therapeutics to a successful IPO and overcame the steep odds of academic discoveries becoming FDA-approved treatments. Dive into the inspiring story behind a breakthrough therapy that is changing lives.

Read All About It

Future of Healthcare

UCSF Innovation Showcase @JPM 2026

The future of healthcare was on full display last night at the UCSF JP Morgan 2026 Innovation Showcase!

Located at 350 California Street, the event brought together the brightest minds in science and venture capital to celebrate the innovative spirit of UCSF. From 40+ groundbreaking technology showcases to high-impact "I to I" meetings between innovators and investors.

Hosted for the third year by our Executive Director Innovation and Entrepreneurship, Aenor Sawyer, MD, the program featured opening remarks from Chancellor Sam Hawgood, MBBS, Provost Catherine Lucey, MD, and Head of Innovation Ventures, Vice Chancellor David Morris, MD, followed by in-depth insights into neuroscience, data science, and artificial intelligence from Stephen Hauser, MD, and Marina Sirota, PhD.

Following the formal presentations, the main lobby hosted a lively reception with cocktails, hors d'oeuvres, and Digital and Tabletop Showcases, co-hosted by UCSF Innovation Ventures and UCSF Development and Alumni Relations. Special thanks to the venue hosts, SKS and SwigCo. The communal space allowed for invaluable networking among scientists, clinicians, and investors, furthering the collaborative spirit that defines the UCSF community.

Thank you to everyone who joined us in shaping the future of medicine!

If you missed this year's event, not to worry, we will be posting the presentations to our website shortly.

Visit our Website

Coming Soon

Where Science Meets Silence:

Innovations in Rare Diseases

February 13, 2026

9:00 am - 4:30 pm

UCSF Mission Bay Conference Center

Rare diseases affect more than 350 million people worldwide. The UCSF Catalyst Program, in partnership with Foundation Ipsen, invites you to our in-person rare disease symposium. With a focus on the interdisciplinary development of new diagnostics, therapeutics, and social advances for patients and their families affected by a rare disease, we hope that all participants will come away from this symposium with an expanded understanding of the field and the inspiration to make a meaningful impact.

This event is a partnership between the Catalyst Program, Ipsen Foundation, and the UCSF Institute of Human Genetics.

News

Continuous Improvement... It's in our DNA

Innovation Ventures joined our colleagues from across UCSF for this celebration of innovation and collaboration for UCSF’s Second Annual Continuous Improvement Fair. This is a chance to connect, learn, and celebrate the UCSF community.

If you missed this year's fair, don't worry, we'll have another one next year!

Success

Catalyst Awardee, Alice Tang, Made the Forbes 30 Under 30 List in Science

Alice Tang has been using AI computational tools to understand and diagnose complex diseases like Alzheimer's. A physician, engineer, and scientist, she pioneered methods to analyze millions of health records using AI, uncovering revelations about diseases, such as the fact that dementia presents differently in men and women.

Read About Her

UCSF Tech in the News

EpiBiologics' $107M series B Funding

Protein degradation biotech EpiBiologics has brought in $107 million in a star-studded series B round headed up by Johnson & Johnson's and Google's respective venture arms.

Tahoe Therapeutics Partners with Alloy Therapeutics to Form Joint Venture and Makes a Deal to Create the Largest Perturbation Dataset for Virtual Cell Models

The new company combines Tahoe’s AI-powered target discovery engine with Alloy’s industry-leading ADC development capabilities to advance two first-in-class oncology programs built on deeply validated tumor targets... and, together with the Arc Institute and Biohub, announced a landmark initiative to generate the largest and most perturbation-rich single-cell dataset for virtual cell models.

Read both articles here...

Read This... And This